EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mutation burden of narrowband ultraviolet B phototherapy (NB-UVB) in human skin: relevance to NB-UVB lifetime exposures and skin cancer surveillance

Joanna C Fowler, Roshan K Sood, George Coltart iD, Chester Lai iD, Noeline Nadarajah, John W Holloway iD, Matthew J J Rose-Zerilli iD, Brian Diffey iD, Philip H Jones iD, Eugene Healy iD

British Journal of Dermatology · 2025

DOI: 10.1093/bjd/ljaf173 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Dermatology, 2025. Verfasst von Joanna C Fowler und 9 weiteren Autor:innen. Beteiligte Einrichtung: Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK. Hauptthemen laut MEDLINE: Ultraviolet Therapy, Mutation, Skin Neoplasms, Psoriasis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Psoriasis Association, Medical Research Council, Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ultraviolet radiation (UVR) is used as treatment for psoriasis and other skin diseases, but UVR can induce DNA mutations that may lead to skin cancer development. While skin cancers have been documented in patients treated with phototherapy, a limited number of epidemiological studies have examined the incidence of skin cancer in people receiving narrowband ultraviolet B (NB-UVB) treatment. Information on the mutagenicity of NB-UVB would help inform about the potential skin cancer risks of this treatment.

Objectives

To determine the mutation burden in human skin resulting from a NB-UVB treatment course and to use this data to estimate the total number of NB-UVB exposures whereupon skin cancer surveillance should begin.

Methods

Biopsies of normal skin were obtained before and after a course of NB-UVB from 16 patients with psoriasis. Epidermal DNA was sequenced using nanorate sequencing (NanoSeq) to determine the mutational signatures and mutation burden from NB-UVB.

Results

The NB-UVB treatment course increased the number of mutations in skin. Median increase in mutation burden was 0.55 substitutions per Mb in infrequently sun-exposed (buttock; n = 14) skin and 0.89 substitutions per Mb in frequently sun-exposed (forearm; n = 10) skin (P < 0.001). Change in mutation burden due to NB-UVB ranged from 1.16- to 10.50-fold in buttock skin and from 0.93- to 2.33-fold in forearm skin. This increase was mainly attributable to UVR exposure-linked mutational signatures, SBS7a and SBS7b, with some evidence that mutational burden was related to the genetic background of the individual. Modelling the change in mutation burden from NB-UVB relative to minimal erythema dose (MED) in comparison with average mutation burden in keratinocyte skin cancers allowed estimation of total lifetime exposures at which patients are likely to require skin cancer surveillance; for patients with a MED equal to 2 standard erythemal doses (SEDs), skin cancer surveillance should be offered at 422, 165 and 58 NB-UVB exposures for those receiving low, typical and high levels of sun exposure, respectively.

Conclusions

A treatment course of NB-UVB causes UVR-induced mutations in the healthy skin of patients with psoriasis. Relating mutation burden to MED and sun behaviour habits allows estimation of when to begin skin cancer surveillance according to total lifetime NB-UVB exposures.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ultraviolet TherapyMutationSkin NeoplasmsPsoriasisNeoplasms, Radiation-InducedHumansMaleFemaleMiddle AgedAdultSkinAged

Autor:innen und Institutionen

  • Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK.
  • Dermatopharmacology, University of Southampton, Southampton General Hospital, Southampton, UK.
  • Dermatology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
  • Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
  • Human Development and Health, University of Southampton, Southampton General Hospital, Southampton, UK.
  • Institute for Life Sciences, University of Southampton, Southampton, UK.

ORCID-Profile: George Coltart, Chester Lai, John W Holloway, Matthew J J Rose-Zerilli, Brian Diffey, Philip H Jones, Eugene Healy

Förderung

  • Psoriasis Association
  • Medical Research Council
  • Wellcome Trust
  • Medical Research Council Clinical Academic Research Partnership

Zitieren

APA

Fowler, J. C., Sood, R. K., Coltart, G., Lai, C., Nadarajah, N., Holloway, J. W., Rose-Zerilli, M. J. J., Diffey, B., Jones, P. H., & Healy, E. (2025). Mutation burden of narrowband ultraviolet B phototherapy (NB-UVB) in human skin: relevance to NB-UVB lifetime exposures and skin cancer surveillance. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljaf173

Vancouver

Fowler JC, Sood RK, Coltart G, Lai C, Nadarajah N, Holloway JW, et al. Mutation burden of narrowband ultraviolet B phototherapy (NB-UVB) in human skin: relevance to NB-UVB lifetime exposures and skin cancer surveillance. British Journal of Dermatology. 2025. doi:10.1093/bjd/ljaf173

BibTeX
@article{Fowler2025,
  author = {Fowler, Joanna C and Sood, Roshan K and Coltart, George and Lai, Chester and Nadarajah, Noeline and Holloway, John W and Rose-Zerilli, Matthew J J and Diffey, Brian and Jones, Philip H and Healy, Eugene},
  title = {Mutation burden of narrowband ultraviolet B phototherapy (NB-UVB) in human skin: relevance to NB-UVB lifetime exposures and skin cancer surveillance},
  journal = {British Journal of Dermatology},
  year = {2025},
  doi = {10.1093/bjd/ljaf173}
}
Kostenlos starten →